当前位置: 首页 >> 检索结果
3401. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.
作者: Antal Bajor.;Hans Törnblom.;Mats Rudling.;Kjell-Arne Ung.;Magnus Simrén.
来源: Gut. 2015年64卷1期84-92页
Bile acids may play a role in the pathogenesis of IBS. We investigated the potential effects of bile acids entering the colon and its role in the symptom pattern in IBS.
3402. The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus.
作者: Massimiliano di Pietro.;David F Boerwinkel.;Mohammed Kareem Shariff.;Xinxue Liu.;Emmanouil Telakis.;Pierre Lao-Sirieix.;Elaine Walker.;George Couch.;Leanne Mills.;Tara Nuckcheddy-Grant.;Susan Slininger.;Maria O'Donovan.;Mike Visser.;Sybren L Meijer.;Philip V Kaye.;Lorenz Wernisch.;Krish Ragunath.;Jacques J G H M Bergman.;Rebecca C Fitzgerald.
来源: Gut. 2015年64卷1期49-56页
Endoscopic surveillance for Barrett's oesophagus (BO) is limited by sampling error and the subjectivity of diagnosing dysplasia. We aimed to compare a biomarker panel on minimal biopsies directed by autofluorescence imaging (AFI) with the standard surveillance protocol to derive an objective tool for dysplasia assessment.
3403. Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.
作者: Sebastian Lunemann.;David F G Malone.;Jan Grabowski.;Kerstin Port.;Vivien Béziat.;Birgit Bremer.;Karl-Johan Malmberg.;Michael P Manns.;Johan K Sandberg.;Markus Cornberg.;Hans-Gustaf Ljunggren.;Heiner Wedemeyer.;Niklas K Björkström.
来源: Gut. 2015年64卷3期469-82页
Although hepatitis delta is considered an immune-mediated disease, adaptive immune responses to hepatitis delta virus (HDV) are hardly detectable. Thus, the role of other immune responses, including those mediated by natural killer (NK) cells, must be considered in HDV pathogenesis and in treatments with immune-stimulating agents such as interferon (IFN)α. However, the phenotype and function of NK cells in chronic HDV infection, or in HDV-infected individuals undergoing IFNα treatment, have not been extensively studied.
3405. OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer.
作者: Jin Qian.;Xuan Kong.;Niantao Deng.;Patrick Tan.;Haoyan Chen.;Jilin Wang.;Zhaoli Li.;Ye Hu.;Weiping Zou.;Jie Xu.;Jing-Yuan Fang.
来源: Gut. 2015年64卷1期37-48页
Octamer transcription factor 1 (OCT1) was found to be expressed in intestinal metaplasia and gastric cancer (GC), but the exact roles of OCT1 in GC remain unclear. The objective of this study was to determine the functional and prognostic implications of OCT1 in GC.
3407. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study.
作者: Shivaram K Bhat.;Damian T McManus.;Helen G Coleman.;Brian T Johnston.;Christopher R Cardwell.;Una McMenamin.;Finian Bannon.;Blanaid Hicks.;Grace Kennedy.;Anna T Gavin.;Liam J Murray.
来源: Gut. 2015年64卷1期20-5页
Endoscopic surveillance of Barrett's oesophagus (BO) provides an opportunity to detect early stage oesophageal adenocarcinoma (OAC). We sought to determine the proportion of OAC patients with a prior diagnosis of BO on a population basis and to evaluate the influence of a prior diagnosis of BO on survival, taking into account lead and length time biases.
3408. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
作者: Raquel Franco Leal.;Núria Planell.;Radhika Kajekar.;Juan J Lozano.;Ingrid Ordás.;Isabella Dotti.;Miriam Esteller.;M Carme Masamunt.;Harsukh Parmar.;Elena Ricart.;Julián Panés.;Azucena Salas.
来源: Gut. 2015年64卷2期233-42页
Anti-tumour necrosis factor α (TNFα) therapy effectively induces and maintains remission in Crohn's disease (CD). Up to 40% of patients, however, fail to respond to anti-TNFα.
3409. Risk of irritable bowel syndrome in first-degree, second-degree and third-degree relatives of affected individuals: a nationwide family study in Sweden.
作者: Rasmus Waehrens.;Henrik Ohlsson.;Jan Sundquist.;Kristina Sundquist.;Bengt Zöller.
来源: Gut. 2015年64卷2期215-21页
IBS aggregates in families, but the familial risk of IBS has only been determined in first-degree relatives and spouses. This nationwide study aimed to determine the familial risk of IBS in first-degree, second-degree, and third-degree relatives and spouses of affected individuals in order to estimate the relative influences of genes and shared family environment.
3410. Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype.
作者: Nuria Seguí.;Matilde Navarro.;Marta Pineda.;Nicole Köger.;Fernando Bellido.;Sara González.;Olga Campos.;Silvia Iglesias.;Rafael Valdés-Mas.;Adriana López-Doriga.;Marta Gut.;Ignacio Blanco.;Conxi Lázaro.;Gabriel Capellá.;Xose S Puente.;Guido Plotz.;Laura Valle.
来源: Gut. 2015年64卷2期355-6页 3411. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma.
作者: Liping Liu.;Chuyong Lin.;Weijiang Liang.;Shu Wu.;Aibin Liu.;Jueheng Wu.;Xin Zhang.;Pengli Ren.;Mengfeng Li.;Libing Song.
来源: Gut. 2015年64卷1期26-36页
Transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) plays an important role in controlling the precisely regulated switch between gene repression and gene activation in transcriptional regulation. We investigated its biological function and clinical significance in esophageal squamous cell carcinoma (ESCC).
3412. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening.
作者: J J Y Sung.;S C Ng.;F K L Chan.;H M Chiu.;H S Kim.;T Matsuda.;S S M Ng.;J Y W Lau.;S Zheng.;S Adler.;N Reddy.;K G Yeoh.;K K F Tsoi.;J Y L Ching.;E J Kuipers.;L Rabeneck.;G P Young.;R J Steele.;D Lieberman.;K L Goh.; .
来源: Gut. 2015年64卷1期121-32页
Since the publication of the first Asia Pacific Consensus on Colorectal Cancer (CRC) in 2008, there are substantial advancements in the science and experience of implementing CRC screening. The Asia Pacific Working Group aimed to provide an updated set of consensus recommendations.
3413. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
作者: Dan Rosmarin.;Claire Palles.;Alistair Pagnamenta.;Kulvinder Kaur.;Guillermo Pita.;Miguel Martin.;Enric Domingo.;Angela Jones.;Kimberley Howarth.;Luke Freeman-Mills.;Elaine Johnstone.;Haitao Wang.;Sharon Love.;Claire Scudder.;Patrick Julier.;Ceres Fernández-Rozadilla.;Clara Ruiz-Ponte.;Angel Carracedo.;Sergi Castellvi-Bel.;Antoni Castells.;Anna Gonzalez-Neira.;Jenny Taylor.;Rachel Kerr.;David Kerr.;Ian Tomlinson.
来源: Gut. 2015年64卷1期111-20页
Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours. About 35% of patients experience dose-limiting toxicity. The few proven genetic biomarkers of 5-FU toxicity are rare variants and polymorphisms, respectively, at candidate loci dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthase (TYMS).
3414. Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.
作者: Aung Ko Win.;Daniel D Buchanan.;Christophe Rosty.;Robert J MacInnis.;James G Dowty.;Gillian S Dite.;Graham G Giles.;Melissa C Southey.;Joanne P Young.;Mark Clendenning.;Michael D Walsh.;Rhiannon J Walters.;Alex Boussioutas.;Thomas C Smyrk.;Stephen N Thibodeau.;John A Baron.;John D Potter.;Polly A Newcomb.;Loïc Le Marchand.;Robert W Haile.;Steven Gallinger.;Noralane M Lindor.;John L Hopper.;Dennis J Ahnen.;Mark A Jenkins.
来源: Gut. 2015年64卷1期101-10页
To estimate risk of colorectal cancer (CRC) for first-degree relatives of CRC cases based on CRC molecular subtypes and tumour pathology features.
3415. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity.
作者: Raquel Gordo-Gilart.;Sara Andueza.;Loreto Hierro.;Pilar Martínez-Fernández.;Daniel D'Agostino.;Paloma Jara.;Luis Alvarez.
来源: Gut. 2015年64卷1期147-55页
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a potentially lethal autosomal recessive liver disease associated with mutations in ABCB4, the gene encoding the canalicular translocator of phosphatidylcholine MDR3. While some affected children benefit from ursodeoxycholic acid (UDCA) therapy, others evolve to end-stage liver disease. We aimed to evaluate whether these different outcomes are related to the impact of ABCB4 mutations.
3416. The human squamous oesophagus has widespread capacity for clonal expansion from cells at diverse stages of differentiation.
作者: Mariagnese Barbera.;Massimiliano di Pietro.;Elaine Walker.;Charlotte Brierley.;Shona MacRae.;Benjamin D Simons.;Phil H Jones.;John Stingl.;Rebecca C Fitzgerald.
来源: Gut. 2015年64卷1期11-9页
Knowledge of the cellular mechanisms involved in homeostasis of human squamous oesophagus in the steady state and following chronic injury is limited. We aimed to better understand these mechanisms by using a functional 3D approach.
3417. XIAP variants in male Crohn's disease.
作者: Yvonne Zeissig.;Britt-Sabina Petersen.;Snezana Milutinovic.;Esther Bosse.;Gabriele Mayr.;Kenneth Peuker.;Jelka Hartwig.;Andreas Keller.;Martina Kohl.;Martin W Laass.;Susanne Billmann-Born.;Heide Brandau.;Alfred C Feller.;Christoph Röcken.;Martin Schrappe.;Philip Rosenstiel.;John C Reed.;Stefan Schreiber.;Andre Franke.;Sebastian Zeissig.
来源: Gut. 2015年64卷1期66-76页
The genetic basis of inflammatory bowel disease (IBD) is incompletely understood. The aim of this study was to identify rare genetic variants involved in the pathogenesis of IBD.
3418. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4.
作者: Liang Li.;Jing Tang.;Baohua Zhang.;Wen Yang.;Miyang LiuGao.;Ruoyu Wang.;Yexiong Tan.;Jianling Fan.;Yanxin Chang.;Jing Fu.;Feng Jiang.;Caiyang Chen.;Yingcheng Yang.;Jin Gu.;Dingming Wu.;Linna Guo.;Dan Cao.;Hengyu Li.;Guangwen Cao.;Mengchao Wu.;Michael Q Zhang.;Lei Chen.;Hongyang Wang.
来源: Gut. 2015年64卷1期156-67页
Liver tumour-initiating cells (T-ICs) are critical for hepatocarcinogenesis. However, the underlying mechanism regulating the function of liver T-ICs remains unclear.
3420. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.
作者: H Fontaine.;S Kahi.;C Chazallon.;M Bourgine.;A Varaut.;C Buffet.;O Godon.;J F Meritet.;Y Saïdi.;M L Michel.;D Scott-Algara.;J P Aboulker.;S Pol.; .
来源: Gut. 2015年64卷1期139-47页
The antiviral efficacy of nucleos(t)ide analogues whose main limitation is relapse after discontinuation requires long-term therapy. To overcome the risk of relapse and virological breakthrough during long-term therapy, we performed a phase I/II, open, prospective, multicentre trial using a HBV envelope-expressing DNA vaccine.
|